BACKGROUND: Rosai-Dorfman disease is an idiopathic, histoproliferative disorder characterized by massive painless lymphadenopathy. The favorable treatment of Rosai-Dorfman disease affecting the central nervous system is surgical resection. Histological and immunohistochemical confirmation is essential for a definitive diagnosis. CASE REPORT: The authors report on a 10-year-old patient with Rosai-Dorfman disease of the central nervous system who presented with increased intracranial pressure. She was treated by stereotactic interstitial irradiation using iodine-125 seeds (interstitial radiosurgery). RESULT: Stereotactic surgery was performed without complications. The patient recovered well to a normal neurologic status. MR images showed a complete remission 49 months after treatment. CONCLUSION: The presented case demonstrates the high efficacy and safety of interstitial irradiation for intracranial Rosai-Dorfman disease. Hence, interstitial radiosurgery could be an appropriate therapeutic option for high-risk resectable intracranial Rosai-Dorfman disease.
BACKGROUND: Rosai-Dorfman disease is an idiopathic, histoproliferative disorder characterized by massive painless lymphadenopathy. The favorable treatment of Rosai-Dorfman disease affecting the central nervous system is surgical resection. Histological and immunohistochemical confirmation is essential for a definitive diagnosis. CASE REPORT: The authors report on a 10-year-old patient with Rosai-Dorfman disease of the central nervous system who presented with increased intracranial pressure. She was treated by stereotactic interstitial irradiation using iodine-125 seeds (interstitial radiosurgery). RESULT: Stereotactic surgery was performed without complications. The patient recovered well to a normal neurologic status. MR images showed a complete remission 49 months after treatment. CONCLUSION: The presented case demonstrates the high efficacy and safety of interstitial irradiation for intracranial Rosai-Dorfman disease. Hence, interstitial radiosurgery could be an appropriate therapeutic option for high-risk resectable intracranial Rosai-Dorfman disease.
Authors: Mohammad Maarouf; Faycal El Majdoub; Christian Bührle; Jürgen Voges; Ralph Lehrke; Martin Kocher; Stefan Hunsche; Harald Treuer; Volker Sturm Journal: Strahlenther Onkol Date: 2010-02-22 Impact factor: 3.621
Authors: Maximilian I Ruge; Martin Kocher; Mohammad Maarouf; Christina Hamisch; Harald Treuer; Jürgen Voges; Volker Sturm Journal: Strahlenther Onkol Date: 2010-12-22 Impact factor: 3.621
Authors: Julien Dinkel; Christian Thieke; Christian Plathow; Patrick Zamecnik; Hermann Prüm; Peter E Huber; Hans-Ulrich Kauczor; Heinz-Peter Schlemmer; Christian M Zechmann Journal: Strahlenther Onkol Date: 2011-06-27 Impact factor: 3.621
Authors: Ralph Mücke; M Heinrich Seegenschmiedt; Reinhard Heyd; Ulrich Schäfer; Franz-Josef Prott; Michael Glatzel; Oliver Micke Journal: Strahlenther Onkol Date: 2009-12-28 Impact factor: 3.621
Authors: Faycal El Majdoub; Clemens Neudorfer; Tobias Blau; Martin Hellmich; Christian Bührle; Martina Deckert; Volker Sturm; Mohammad Maarouf Journal: Strahlenther Onkol Date: 2015-08-26 Impact factor: 3.621